Browsing by Author "Badia-Ramentol, Jordi"

Sort by: Order: Results:

  • Challenges and therapeutic opportunities in the dMMR/MSI-H colorectal cancer landscape
    Mulet Margalef, Núria; Linares Aceituno, Jenniffer Lissethe; Badia-Ramentol, Jordi; Jimeno, Mireya; Sanz Monte, Carolina; Manzano Mozo, José Luis; Calon, Alexandre (MDPI, 2023)
    About 5 to 15% of all colorectal cancers harbor mismatch repair deficient/microsatellite instability–high status (dMMR/MSI-H) that associates with high tumor mutation burden and increased immunogenicity. As a result, and ...
  • Determinants and functions of CAFs secretome during cancer progression and therapy
    Linares Aceituno, Jenniffer Lissethe; Marín Jiménez, Juan A.; Badia-Ramentol, Jordi; Calon, Alexandre (Frontiers, 2021)
    Multiple lines of evidence are indicating that cancer development and malignant progression are not exclusively epithelial cancer cell-autonomous processes but may also depend on crosstalk with the surrounding tumor ...
  • Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy
    Linares Aceituno, Jenniffer Lissethe; Sallent-Aragay, Anna; Badia-Ramentol, Jordi; Recort-Bascuas, Alba; Manero Rupérez, Noemí; Rivas, Elisa; Zwick, Melissa; Iglesias Coma, Mar; Orrillo, Mayra; Garrido, Marta; Navarro Medrano, Pilar; Montagut Viladot, Clara; Calon, Alexandre (Nature Research, 2023)
    A substantial proportion of cancer patients do not benefit from platinum-based chemotherapy (CT) due to the emergence of drug resistance. Here, we apply elemental imaging to the mapping of CT biodistribution after therapy ...
  • Minimal residual disease, metastasis and immunity
    Badia-Ramentol, Jordi; Linares Aceituno, Jenniffer Lissethe; Gómez-Llonín, Andrea; Calon, Alexandre (MDPI, 2021)
    Progression from localized to metastatic disease requires cancer cells spreading to distant organs through the bloodstream. Only a small proportion of these circulating tumor cells (CTCs) survives dissemination due to ...
  • Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors
    Rivas, Elisa; Linares Aceituno, Jenniffer Lissethe; Zwick, Melissa; Gómez-Llonín, Andrea; Guiu, Marc; Labernadie, Anna; Badia-Ramentol, Jordi; Lladó, Anna; Bardia, Lídia; Pérez-Núñez, Iván; Martínez-Ciarpaglini, Carolina; Tarazona, Noelia; Sallent-Aragay, Anna; Garrido, Marta; Celià-Terrassa, Toni; Burgués, Octavio; Gomis, Roger R.; Albanell Mestres, Joan; Calon, Alexandre (Nature Research, 2022)
    About 50% of human epidermal growth factor receptor 2 (HER2)+ breast cancer patients do not benefit from HER2-targeted therapy and almost 20% of them relapse after treatment. Here, we conduct a detailed analysis of two ...
  • The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice
    Badia-Ramentol, Jordi; Gimeno-Valiente, Francisco; Duréndez, Elena; Martínez-Ciarpaglini, Carolina; Linares Aceituno, Jenniffer Lissethe; Iglesias Coma, Mar; Cervantes, Andrés; Calon, Alexandre; Tarazona, Noelia (Elsevier, 2023)
    Adjuvant chemotherapy following surgical intervention remains the primary treatment option for patients with localized colorectal cancer (CRC). However, a significant proportion of patients will have an unfavorable outcome ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking